Organon & Co. (OGN)
Company Info
US68622V1061
68622V106
Jun 2, 2021
Highlights
$2.28B
$3.14
2.79
$6.29B
$3.60B
$1.50B
$8.01 - $22.24
$16.17
10.08%
4.41
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Organon & Co. (OGN) returned -38.15% year-to-date (YTD) and -55.75% over the past 12 months.
OGN
-38.15%
-16.26%
-38.61%
-55.75%
N/A
N/A
^GSPC (Benchmark)
1.30%
12.94%
1.49%
12.48%
15.82%
10.87%
Monthly Returns
The table below presents the monthly returns of OGN, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 4.29% | -2.41% | -0.13% | -13.16% | -29.92% | -38.15% | |||||||
| 2024 | 15.46% | 6.17% | 7.98% | -1.01% | 16.20% | -2.95% | 5.60% | 3.68% | -14.41% | -1.83% | -13.99% | -5.99% | 9.92% |
| 2023 | 7.88% | -17.86% | -3.96% | 4.72% | -20.22% | 7.32% | 5.62% | 1.15% | -20.95% | -14.80% | -21.54% | 27.39% | -45.12% |
| 2022 | 4.79% | 17.90% | -6.43% | -7.44% | 18.37% | -11.09% | -6.01% | -9.25% | -17.98% | 11.88% | 0.57% | 7.34% | -4.86% |
| 2021 | -14.18% | -4.13% | 17.79% | -3.25% | 12.08% | -19.75% | 4.17% | -12.15% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of OGN is 4, meaning it’s performing worse than 96% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Organon & Co. (OGN) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Organon & Co. provided a 9.51% dividend yield over the last twelve months, with an annual payout of $0.86 per share. The company has been increasing its dividends for 3 consecutive years.
| Period | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Dividend | $0.86 | $1.12 | $1.12 | $1.12 | $0.56 |
Dividend yield | 9.51% | 7.51% | 7.77% | 4.01% | 1.84% |
Monthly Dividends
The table displays the monthly dividend distributions for Organon & Co.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | $0.00 | $0.28 | $0.00 | $0.00 | $0.02 | $0.30 | |||||||
| 2024 | $0.00 | $0.28 | $0.00 | $0.00 | $0.28 | $0.00 | $0.00 | $0.28 | $0.00 | $0.00 | $0.28 | $0.00 | $1.12 |
| 2023 | $0.00 | $0.28 | $0.00 | $0.00 | $0.28 | $0.00 | $0.00 | $0.28 | $0.00 | $0.00 | $0.28 | $0.00 | $1.12 |
| 2022 | $0.00 | $0.28 | $0.00 | $0.00 | $0.28 | $0.00 | $0.00 | $0.28 | $0.00 | $0.00 | $0.28 | $0.00 | $1.12 |
| 2021 | $0.28 | $0.00 | $0.00 | $0.28 | $0.00 | $0.56 |
Dividend Yield & Payout
Dividend Yield
Organon & Co. has a dividend yield of 9.51%, which means its dividend payment is significantly above the market average.
Payout Ratio
Organon & Co. has a payout ratio of 21.99%, which is below the market average. This means Organon & Co. returns a smaller proportion of its earnings to shareholders as dividends, suggesting it retains a higher portion for reinvestment, growth, or debt payment.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Organon & Co.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Organon & Co. was 75.77%, occurring on May 14, 2025. The portfolio has not yet recovered.
The current Organon & Co. drawdown is 72.75%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -75.77% | Mar 3, 2022 | 803 | May 14, 2025 | — | — | — |
| -23.11% | Jun 4, 2021 | 4 | Jun 9, 2021 | 96 | Oct 25, 2021 | 100 |
| -22.09% | Nov 2, 2021 | 27 | Dec 9, 2021 | 53 | Feb 25, 2022 | 80 |
| -3.22% | Oct 26, 2021 | 2 | Oct 27, 2021 | 3 | Nov 1, 2021 | 5 |
| -0.64% | Feb 28, 2022 | 1 | Feb 28, 2022 | 2 | Mar 2, 2022 | 3 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Organon & Co. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Organon & Co., comparing actual results with analytics estimates. The company met analyst expectations for EPS in the past quarter.
Valuation
The Valuation section provides an overview of how Organon & Co. is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for OGN, comparing it with other companies in the Drug Manufacturers - General industry. Currently, OGN has a P/E ratio of 2.8. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for OGN relative to other companies in the Drug Manufacturers - General industry. Currently, OGN has a P/S ratio of 0.4. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for OGN in comparison with other companies in the Drug Manufacturers - General industry. Currently, OGN has a P/B value of 4.2. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |